Indeed, there are suggestions that IgE may not only be able to complement IgG therapy, but in some cases, may offer superior benefit—for example, in some model systems, IgE antibodies were capable of mediating antibody-dependent cell-mediated cytotoxicity (ADCC) against corresponding cancer cells at greater superiority compared to a corresponding IgG1 (70% vs. 30% in ADCC/ADCP assays) [18,90]. This evidence concerns the gene IGHE and cancer.